Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jazz Pharmaceuticals has said that the FDA has issued an approvable letter for once-a-day Luvox CR extended-release capsules for the treatment of two anxiety disorders.
Subscribe to our email newsletter
Jazz and Solvay Pharmaceuticals are seeking marketing approval for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).